AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel Cucurbitacins and Estrone analogs as Potential Drug Candidates for the Treatment of Prostate Cancer

Technology Benefits

The potential of cucurbitacins and their analogs as lead drug candidates for the treatment of prostate cancer. The compounds developed have the potential to reduce cancer resistance through stronger androgen receptor binding as well as perform better than the current treatments in the marketplace and lower hepatotoxicity. Cucurbitacins have more potential as multifaceted drugs as they reduce inflammation due to carcinogenicity and play an important role in controlling Hsp90.

Detailed Technology Description

Several estrone and cucurbitane analogs have been identified through molecular modeling to target the androgen receptor and therefore may be applicable in the treatment of prostate cancer. In vitro and in vivo results showed several analogs performing better than the standard nilutamide. Further evidence of androgen receptor binding has been generated through an androgen receptor competitive assay. Several estrone and cucurbitacin analogs showed stronger or similar binding to the AR than nilutamide.

Country/Region

USA

For more information, please click Here